Su Seong Lee

Our group develops peptide-based theranostic agents that integrate precise diagnosis with targeted therapy. We design peptide-targeting ligands to selectively recognize disease-related biomarkers as well as cellular and organ-specific targets. By combining high-throughput screening with computational methods, we aim to enhance target specificity, minimize off-target effects, reduce treatment doses, and improve patient safety. Clinically, these approaches may support more accurate patient stratification, and more effective personalized treatment strategies.

We also develop antimicrobial peptides to combat antibiotic-resistant bacterial infections and peptide-based anticancer vaccines to support cancer immunotherapy. Through rational design and computationally assisted optimization, we create innovative peptide agents with potential applications in infection control, personalized medicine, and improved therapeutic outcomes. Scientifically, this work advances peptide chemistry, target recognition, and translational drug development for diseases with urgent unmet clinical needs.